Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
154 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Autism - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Autism - Pipeline Review, H1 2015', provides an overview of the Autism's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Autism - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Autism Overview 10 Therapeutics Development 11 Pipeline Products for Autism - Overview 11 Pipeline Products for Autism - Comparative Analysis 12 Autism - Therapeutics under Development by Companies 13 Autism - Therapeutics under Investigation by Universities/Institutes 16 Autism - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Autism - Products under Development by Companies 21 Autism - Products under Investigation by Universities/Institutes 23 Autism - Companies Involved in Therapeutics Development 24 Addex Therapeutics Ltd 24 Avanir Pharmaceuticals, Inc. 25 BioCrea GmbH 26 BrainStorm Cell Therapeutics Inc. 27 Cellceutix Corporation 28 Confluence Pharmaceuticals LLC 29 Curemark, LLC 30 Edison Pharmaceuticals, Inc. 31 Egenix, Inc. 32 F. Hoffmann-La Roche Ltd. 33 Heptares Therapeutics Ltd. 34 Intra-Cellular Therapies, Inc. 35 MedDay 36 Merz Pharma GmbH & Co. KgaA 37 Mitsubishi Tanabe Pharma Corporation 38 Mnemosyne Pharmaceuticals, Inc. 39 Novartis AG 40 Omeros Corporation 41 Otsuka Holdings Co., Ltd. 42 Reviva Pharmaceuticals Inc. 43 Saniona AB 44 Sumitomo Dainippon Pharma Co., Ltd. 45 Teva Pharmaceutical Industries Limited 46 Autism - Therapeutics Assessment 47 Assessment by Monotherapy Products 47 Assessment by Combination Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 (dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 acamprosate calcium - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ADX-88178 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 aripiprazole - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 carbetocin - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CM-AT - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CN-2097 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 CNDO-201 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drug for Autism - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Drug for Autism Spectrum Disorders - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 fingolimod hydrochloride - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 fluoxetine - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 glatiramer acetate - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 HTL-14242 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ITI-007 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 KM-391 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 lurasidone hydrochloride - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 MD-1103 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 memantine hydrochloride - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 oxytocin - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 oxytocin - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 RG-7314 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 RP-5063 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecule to Modulate GABRA5 Receptor for Alzheimer's Disease, Schizophrenia and Autism - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 Small Molecule to Target GPR63 for Autism - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Stem Cell Therapy for Autism - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 suramin hexasodium - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 vatiquinone - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 Autism - Recent Pipeline Updates 108 Autism - Dormant Projects 144 Autism - Discontinued Products 146 Autism - Product Development Milestones 147 Featured News & Press Releases 147 Jun 26, 2014: Coronado Biosciences Reports Topline Results from Investigator Initiated Pilot Study of TSO in Adults with Autism Spectrum Disorder 147 May 14, 2014: Coronado Biosciences Initiates Phase 2a Clinical Study of TSO in Pediatric Patients With Autism Spectrum Disorder 147 Dec 12, 2013: Coronado Biosciences Announces Presentation of Interim Data From Autism Study at Neuropsychopharmacology Meeting 147 Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment 148 Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 148 Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 149 Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 149 Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism 150 Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model 150 Nov 12, 2012: Coronado Biosciences Announces Initiation Of Investigator-initiated Study Evaluating TSO In Autism Spectrum Disorders 151 Appendix 153 Methodology 153 Coverage 153 Secondary Research 153 Primary Research 153 Expert Panel Validation 153 Contact Us 154 Disclaimer 154
List of Tables Number of Products under Development for Autism, H1 2015 11 Number of Products under Development for Autism - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Comparative Analysis by Unknown Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2015 23 Autism - Pipeline by Addex Therapeutics Ltd, H1 2015 24 Autism - Pipeline by Avanir Pharmaceuticals, Inc., H1 2015 25 Autism - Pipeline by BioCrea GmbH, H1 2015 26 Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H1 2015 27 Autism - Pipeline by Cellceutix Corporation, H1 2015 28 Autism - Pipeline by Confluence Pharmaceuticals LLC, H1 2015 29 Autism - Pipeline by Curemark, LLC, H1 2015 30 Autism - Pipeline by Edison Pharmaceuticals, Inc., H1 2015 31 Autism - Pipeline by Egenix, Inc., H1 2015 32 Autism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 33 Autism - Pipeline by Heptares Therapeutics Ltd., H1 2015 34 Autism - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 35 Autism - Pipeline by MedDay, H1 2015 36 Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2015 37 Autism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 38 Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015 39 Autism - Pipeline by Novartis AG, H1 2015 40 Autism - Pipeline by Omeros Corporation, H1 2015 41 Autism - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 42 Autism - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 43 Autism - Pipeline by Saniona AB, H1 2015 44 Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 45 Autism - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 46 Assessment by Monotherapy Products, H1 2015 47 Assessment by Combination Products, H1 2015 48 Number of Products by Stage and Target, H1 2015 50 Number of Products by Stage and Mechanism of Action, H1 2015 52 Number of Products by Stage and Route of Administration, H1 2015 54 Number of Products by Stage and Molecule Type, H1 2015 56 Autism Therapeutics - Recent Pipeline Updates, H1 2015 108 Autism - Dormant Projects, H1 2015 144 Autism - Dormant Projects (Contd..1), H1 2015 145 Autism - Discontinued Products, H1 2015 146
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
